1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

TABLE 1: Characteristics of patients with and without hemorrhagic transformation after IA reperfusion therapy
Hemorrhagic Transformation No Hemorrhagic Transformation P Value
Patient demographics 
Number of cases 13 19 
Mean age (years) 65.2 67.9 .63
Female (%) 46.2% 52.6% .99
Clinical characteristics 
Left-hemispheric MCA lesions (%) 33.3% 38.5% .20
Mean initial NIHSS score 19.9 17.6 .20
Mean initial serum glucose (mg/dl) 186 173 .63
Patients on antithrombotics (%) 53.8% 42.1% .99
Treatment characteristics 
Mean time from symptoms to initial image (hours) 2.04 1.77 .56
Mean time from symptoms to treatment (hours) 4.33 4.22 .80
Mean time from treatment to recanalization (hours) 0.92 0.95 .92
Patients with recanalization <6 h after onset (%) 69.2% 57.9% .71
Patients receiving GP-IIbIIIa inhibitors (%) 54.0% 52.9% .99
Patients receiving IV tPA (%) 15.4% 15.8% 1.0
Mean dose IA tPA (all patients) (mg) 13.7 10.9 .31
Mean total dose tPA (IV + IA patients) (mg) 24.5 22.9 .87
Note.—GP indicates glycoprotein; IA, intraarterial; IV, intravenous; MCA, middle cerebral artery; NIHSS, National Institutes of Health Stroke Scale; tPA, tissue plasminogen activator.